Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rineterkib hydrochloride (compound B) is an orally active RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer[1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | Inquiry | $ 789.00 |
Description | Rineterkib hydrochloride (compound B) is an orally active RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer[1]. |
In vitro | ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice[1]. |
Molecular Weight | 614.89 |
Formula | C26H28BrClF3N5O2 |
CAS No. | 1715025-34-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 220 mg/mL, Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Rineterkib hydrochloride 1715025-34-5 Rineterkib Hydrochloride inhibitor inhibit